SCHEMBL402859

SCHEMBL402859

O=C(Nc1ccc(Cl)c(NC(=O)c2ccccc2)c1)c1ccc(N2CCOCC2)nc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.64
SMN1; SMN2 Q16637 6/20 0.64
LMNA P02545 2/20 0.64
HTT P42858 2/20 0.64
RAB9A P51151 3/20 0.59
SMO Q99835 1/20 0.59
CYP1A2 P05177 1/20 0.59
CYP2C19 P33261 1/20 0.59
KMT2A Q03164 3/20 0.57
MEN1 O00255 2/20 0.57
STAT3 P40763 1/20 0.57
KCNQ3 O43525 1/20 0.56
KCNQ2 O43526 1/20 0.56
MAPK1 P28482 1/20 0.55
DGAT1 O75907 2/20 0.54
CNR1 P21554 1/20 0.54
KDM4E B2RXH2 1/20 0.54
NPC1 O15118 2/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
PPARG P37231 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL401175 0.88 SMO (0.61) MAPTSMN1; SMN2LMNAHTTRAB9A
SCHEMBL402625 0.87 SMO (0.60) MAPTSMN1; SMN2LMNAHTTRAB9A
SCHEMBL402823 0.87 SMO (0.59) MAPTSMN1; SMN2LMNAHTTRAB9A
SCHEMBL10238347 0.87 KMT2A (0.63) MAPTSMN1; SMN2LMNAHTTRAB9A
SCHEMBL404119 0.86 CHRM1 (0.66) MAPTSMN1; SMN2RAB9ASMOKMT2A
SCHEMBL10238480 0.85 SMO (0.58) MAPTSMN1; SMN2LMNAHTTRAB9A
SCHEMBL399009 0.85 SMO (0.56) MAPTSMN1; SMN2LMNAHTTRAB9A
SCHEMBL1018085 0.84 MTOR (0.63) MAPTSMN1; SMN2LMNAHTTRAB9A
SCHEMBL400036 0.84 SMO (0.68) MAPTSMN1; SMN2LMNAHTTRAB9A
SCHEMBL402922 0.84 HIF1A (0.63) MAPTSMN1; SMN2LMNAHTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1957461-B1 BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING GENENTECH INC (US) 2016-11-02 EP claimed
US-8101610-B2 Blocking signals; anticancer agents GENENTECH, INC. (US) 2012-01-24 US claimed
US-20080269215-A1 Bisamide Inhibitors of Hedgehog Signaling GENENTECH INC. (US) 2008-10-30 US claimed
EP-1957461-A1 BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING Genentech, Inc. (US) 2008-08-20 EP claimed
WO-2007059157-A1 BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING GENENTECH, INC. (US) 2007-05-24 WO claimed
EP-1957461-B1 BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING GENENTECH INC (US) 2016-11-02 EP disclosed
US-8101610-B2 Blocking signals; anticancer agents GENENTECH, INC. (US) 2012-01-24 US disclosed
US-8101610-B2 Blocking signals; anticancer agents GENENTECH, INC. (US) 2012-01-24 US disclosed
US-8101610-B2 Blocking signals; anticancer agents GENENTECH, INC. (US) 2012-01-24 US disclosed
US-20080269215-A1 Bisamide Inhibitors of Hedgehog Signaling GENENTECH INC. (US) 2008-10-30 US disclosed
US-20080269215-A1 Bisamide Inhibitors of Hedgehog Signaling GENENTECH INC. (US) 2008-10-30 US disclosed
US-20080269215-A1 Bisamide Inhibitors of Hedgehog Signaling GENENTECH INC. (US) 2008-10-30 US disclosed
EP-1957461-A1 BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING Genentech, Inc. (US) 2008-08-20 EP disclosed
WO-2007059157-A1 BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING GENENTECH, INC. (US) 2007-05-24 WO disclosed
WO-2007059157-A1 BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING GENENTECH, INC. (US) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269215-A1 Bisamide Inhibitors of Hedgehog Signaling SHH, GLI1, SMO MAPT 2726/4885SMN1; SMN2 4415/4885LMNA 3681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.